Mesonephric adenocarcinoma treated with paclitaxel-carboplatin adjuvant chemotherapy: A case report

J. J. Noh, H. Jung, C. H. Choi

Research output: Contribution to journalArticlepeer-review

Abstract

The authors describe a case of a mesonephric adenocarcinoma of the meso-ovarium and meso-salpinx in a 52-year-old woman. The patient underwent total laparoscopic hysterectomy, bilateral salpingo-oophorectomy, followed by adjuvant chemotherapy with paclitaxel and carboplatin for six cycles with three-week intervals in between. The patient remained free of disease for 18 months with good general conditions. They also reviewed the clinical, pathological, and immunohistochemical characteristics of 42 published case reports of mesonephric adenocarcinoma. The most common presentation of the disease was vaginal bleeding, followed by low abdominal pain. Among the 42 cases reviewed, only three patients were given the correct diagnosis preoperatively. A significant portion of them showed positive immunoreactivity for CD10, vimentin, and calretinin. The authors also found that AE1/AE3, CK7, EMA, CD10, and vimentin are typically positive while ER, PR, and CEA are usually negative. Among the cases reviewed, adjuvant chemotherapy was performed in 11 (26.2%) patients while adjuvant radiotherapy was performed in 16 (38.1%) patients. A number of chemotherapeutic regimens have been used but responses to such regimens are still inconclusive. Although further experiences are needed, surgical removal of the mass followed by paclitaxel and carboplatin adjuvant chemotherapy may be considered as a viable option for treatment.

Original languageEnglish
Pages (from-to)679-683
Number of pages5
JournalEuropean Journal of Gynaecological Oncology
Volume40
Issue number4
DOIs
StatePublished - 2019
Externally publishedYes

Keywords

  • Carboplatin
  • Chemotherapy
  • Hysterectomy
  • Mesonephric adenocarcinoma
  • Paclitaxel

Fingerprint

Dive into the research topics of 'Mesonephric adenocarcinoma treated with paclitaxel-carboplatin adjuvant chemotherapy: A case report'. Together they form a unique fingerprint.

Cite this